A phase II study of docetaxel/carboplatin as secondline treatment in patients with refractory or relapsed SCLC
- Conditions
- refractory small cell lungcancerSCLC-ED10006436
- Registration Number
- NL-OMON33924
- Lead Sponsor
- Jeroen Bosch Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Histologically proven SCLC at the first diagnosis.
Refractory or relapsed SCLC
Measurable disease according to RECIST criteria
Patients must have fully recovered from toxic effects of previous antitumour therapy.
Age > 18 years.
WHO performance status 0,1 or 2 (Appendix II).
More than one line of chemotherapy for metastatic disease
Pregnant or lactating women or women of childbearing potential not adhering to adequate anti conceptive measures
History of other invasive malignancy within the last 5 years (other than non melanoma skin cancer or excised cervical carcinoma in situ).
Clinical evidence CNS metastasis.
Symptomatic peripheral neuropathy > grade 2 according (NCI CTC, Appendix III)
Definite contraindications for the use of corticosteroids
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method